Literature DB >> 9442978

CT and MRI evaluation of musculoskeletal infection.

L D Ma1, F J Frassica, D A Bluemke, E K Fishman.   

Abstract

While the plain film and nuclear medicine bone scan are still the traditional imaging modalities used in the evaluation of musculoskeletal infection, the cross-sectional imaging modalities, computed tomography (CT) and magnetic resonance imaging (MRI), have become critical in the delineation of many types of musculoskeletal infection. In particular, the evaluation of soft tissue infections, including cellulitus, myositis, fasciitis, abscess, and septic arthritis are often best evaluated by MRI or CT due to their excellent anatomic resolution and soft tissue contrast. Even in osseous infection, CT and MRI can give better anatomic delineation of the extent of infection. In cases where the plain film and nuclear medicine bone scan findings are complicated due to previous surgery, trauma, or underlying illness, the anatomic resolution and soft tissue contrast provided by MRI and CT are often necessary to determine if underlying infection exists. MRI's visualization of the bone marrow allows for the sensitive detection of osteomyelitis, although specificity for the diagnosis of osteomyelitis is aided by other findings, including cortical destruction. The CT and MRI findings in the spectrum of musculoskeletal infections are discussed and contrasted, and pitfalls in their evaluation of musculoskeletal infection are described.

Entities:  

Mesh:

Year:  1997        PMID: 9442978

Source DB:  PubMed          Journal:  Crit Rev Diagn Imaging        ISSN: 1040-8371


  16 in total

Review 1.  Radionuclide imaging of spinal infections.

Authors:  Filip Gemmel; Nicolas Dumarey; Christopher J Palestro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-10       Impact factor: 9.236

Review 2.  Necrotizing fasciitis: an urgent diagnosis.

Authors:  Silvia Paz Maya; Delfina Dualde Beltrán; Pierre Lemercier; Carlos Leiva-Salinas
Journal:  Skeletal Radiol       Date:  2014-01-29       Impact factor: 2.199

3.  Comparison of [18 F]FDG PET/CT and MRI in the diagnosis of active osteomyelitis.

Authors:  Anastas Demirev; René Weijers; Jan Geurts; Felix Mottaghy; Geert Walenkamp; Boudewijn Brans
Journal:  Skeletal Radiol       Date:  2014-03-08       Impact factor: 2.199

4.  Diagnostic value of 18F-FDG PET/CT in trauma patients with suspected chronic osteomyelitis.

Authors:  Anna Hartmann; Karim Eid; Claudio Dora; Otmar Trentz; Gustav K von Schulthess; Katrin D M Stumpe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-29       Impact factor: 9.236

Review 5.  Microbiology and management of myositis.

Authors:  Itzhak Brook
Journal:  Int Orthop       Date:  2004-08-26       Impact factor: 3.075

Review 6.  Expanding role of 18F-fluoro-D-deoxyglucose PET and PET/CT in spinal infections.

Authors:  Filip Gemmel; Paul C Rijk; James M P Collins; Thierry Parlevliet; Katrin D Stumpe; Christopher J Palestro
Journal:  Eur Spine J       Date:  2010-01-06       Impact factor: 3.134

7.  Long Bone Osteomyelitis.

Authors:  Luca Lazzarini; Fausto De Lalla; Jon T. Mader
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

Review 8.  Imaging of musculoskeletal soft tissue infections.

Authors:  Marcin B Turecki; Mihra S Taljanovic; Alana Y Stubbs; Anna R Graham; Dean A Holden; Tim B Hunter; Lee F Rogers
Journal:  Skeletal Radiol       Date:  2009-08-28       Impact factor: 2.199

9.  An elderly patient presenting with hip pain following a fall: an unusual presentation of necrotising fasciitis.

Authors:  Daniel Markeson; Reet Nijjar; Evgenios Evgeniou; Mahendra Kulkarni
Journal:  BMJ Case Rep       Date:  2012-10-06

10.  Rapid normalization of osseous FDG uptake following traumatic or surgical fractures.

Authors:  Hongming Zhuang; Joseph W Sam; Thomas K Chacko; Paulo S Duarte; Marc Hickeson; Qi Feng; Kozaim Z Nakhoda; Liang Guan; Phillip Reich; Shirley M Altimari; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-22       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.